Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Long-Term Deferred Tax (2016)

Alaunos Therapeutics (TCRT) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $10.2 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Long-Term Deferred Tax changed N/A year-over-year to $10.2 million, compared with a TTM value of $10.2 million through Dec 2016, changed N/A, and an annual FY2016 reading of $10.2 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $10.2 million for Q4 2016 at Alaunos Therapeutics.
  • Across five years, Long-Term Deferred Tax topped out at $10.2 million in Q4 2016 and bottomed at $10.2 million in Q4 2016.